High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia

Shigematsu, Akio; Kobayashi, Naoki; Yasui, Hiroshi; Shindo, Motohiro; Kakinoki, Yasutaka; Koda, Kyuhei; Iyama, Satoshi; Kuroda, Hiroyuki; Tsutsumi, Yutaka; Imamura, Masahiro; Teshima, Takanori

High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia

Shigematsu, Akio; Kobayashi, Naoki; Yasui, Hiroshi et al.

Biology of Blood and Marrow Transplantation, 2014, 20(6), 801-805

Permalink : https://hdl.handle.net/2115/56537

このアイテムのアクセス数:1,053件（2026-10-18 12:50 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Biol Blood Marrow Transplant_20(6)_801-805	pdf	413 KB	1,006

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/56537
タイトル	High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia
著者	Shigematsu, Akio ; Kobayashi, Naoki ; Yasui, Hiroshi ; Shindo, Motohiro ; Kakinoki, Yasutaka ; Koda, Kyuhei ; Iyama, Satoshi ; Kuroda, Hiroyuki ; Tsutsumi, Yutaka ; Imamura, Masahiro ; Teshima, Takanori
著者名 Shigematsu, Akio
著者名 Kobayashi, Naoki
著者名 Yasui, Hiroshi
著者名 Shindo, Motohiro
著者名 Kakinoki, Yasutaka
著者名 Koda, Kyuhei
著者名 Iyama, Satoshi
著者名 Kuroda, Hiroyuki
著者名 Tsutsumi, Yutaka
e-Rad_Researcher 20160062 著者名 Imamura, Masahiro
e-Rad_Researcher 40284096 著者名 Teshima, Takanori
言語	英語
キーワード	Adult T cell leukemia
	Allogeneic stem cell transplantation
	Region-wide study
	Soluble interleukin-2 receptor
	Prognostic factor
発行日	2014-06
出版者	Elsevier
収録物名	Biology of Blood and Marrow Transplantation
巻(号)	20(6)
ページ	801-805
抄録	The prognosis for adult T cell leukemia/lymphoma (ATL) is very poor, and only allogeneic hematopoietic stem cell transplantation (allo-SCT) has been considered to be a curative treatment for ATL. In this study, we retrospectively analyzed data for patients who had received allo-SCT for ATL in Hokkaido, the northernmost island of Japan, to determine prognostic factors. Fifty-six patients with a median age of 57 years received allo-SCT. Twenty-eight (50.0%) patients had acute type and 22 (46.4%) had lymphoma type. Twenty-three (41.1%) patients received allo-SCT in complete remission (CR), whereas the others were in non-CR. Seventeen (30.4%) patients received myeloablative conditioning and the others received reduced-intensity conditioning. With a median follow-up period of 48 months (range, 17 to 134 months), 1-year overall survival (OS) and 5-year OS rates were 55.4% and 46.1%, respectively. The survival curve reached a plateau at 22 months after stem cell transplantation (SCT). Male sex, high level of serum soluble interleukin-2 receptor (sIL-2R) at SCT, and non-CR at SCT were determined to be significant risk factors for OS. A high level of sIL-2R at SCT was a risk factor for poor OS in patients with non-CR at SCT by univariate analysis (P = .02), and it remained significant after adjustment by sex (hazard ratio, 2.73 [95% confidence interval, 1.07 to 7.90]). A high level of sIL-2R at SCT was also determined to be a risk factor for disease progression (P = .02). This region-wide study showed encouraging results for survival after allo-SCT for ATL and demonstrated for the first time that a high level of sIL-2R at SCT predicts worse SCT outcome. (C) 2014 American Society for Blood and Marrow Transplantation.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
PISSN	1083-8791
NCID	AA11361618
関連情報	PMID 24565990
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.bbmt.2014.02.014